US Patent

US8324208 — Prolyl hydroxylase inhibitors

Composition of Matter · Assigned to GlaxoSmithKline LLC · Expires 2028-12-11 · 3y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects certain pyrimidinetrione N-substituted glycine derivatives that inhibit HIF prolyl hydroxylases.

USPTO Abstract

The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

Drugs covered by this patent

Patent Metadata

Patent number
US8324208
Jurisdiction
US
Classification
Composition of Matter
Expires
2028-12-11
Drug substance claim
Yes
Drug product claim
Yes
Assignee
GlaxoSmithKline LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.